Skip to main content

Table 3 VEGF-C/VEGFR3, VEGF-D/VEGFR2, and VEGF-D/VEGFR3 ratios and association with clinico-pathological features in mismatch repair-proficient colorectal cancer.

From: Role of the VEGF ligand to receptor ratio in the progression of mismatch repair-proficient colorectal cancer

   VEGF-C/VEGFR3 VEGF-D/VEGFR2 VEGF-D/VEGFR3
    P-value   P-value   P-value
TNM stage I+II 6.0 ± 21.0;
0.95
0.265 1.8 ± 9.1;
1.0
0.55 6.6 ± 22.4;
1.03
0.981
  III 3.99 ± 13.4;
0.79
  0.94 ± 0.1;
1.0
  13.2 ± 32.0;
1.05
 
  IV 5.93 ± 19.7;
1.0
  4.67 ± 18.8;
1.0
  7.14 ± 23.3;
1.05
 
Tumour grade G1-2 5.28 ± 18.3;
0.95
0.116 2.46 ± 11.9;
1.0
0.274 8.34 ± 25.4;
1.05
0.317
  G3 4.94 ± 18.1;
0.75
  0.96 ± 0.17;
1.0
  11.9 ± 30.5;
1.0
 
Vascular invasion Absent 4.56 ± 16.8;
0.95
0.928 2.2 ± 10.5;
1.0
0.53 8.75 ± 26.2;
1.0
0.158
  Present 6.74 ± 21.4;
0.95
  2.34 ± 11.6;
1.0
  9.7 ± 27.1;
1.05
 
Tumour border configuration PM 3.9 ± 15.7;
0.95
0.349 1.82 ± 9.04;
1.0
0.172 7.62 ± 24.5;
1.0
0.437
  IM 6.67 ± 20.7;
0.95
  2.53 ± 12.3;
1.0
  10.5 ± 28.3;
1.05
 
PTL infiltration Absent 6.15 ± 20.1;
0.95
0.733 1.96 ± 9.9;
1.0
0.538 10.6 ± 28.9;
1.0
0.575
  Present 1.09 ± 1.5;
0.85
  3.18 ± 14.4;
1.0
  1.79 ± 3.0;
1.05
 
  1. Mean ± SD, median values. Kruskal-Wallis or Wilcoxon Rank Sum Test. PM = pushing/expanding margin; IM = infiltrating margin; PTL = peritumoral lymphocytic.